Cargando…
Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
PURPOSE: Evogliptin (DA-1229) is a novel, potent, and selective dipeptidyl peptidase 4 (DPP-4) inhibitor for treating type 2 diabetes mellitus. This study investigates the effect of rifampicin on evogliptin pharmacokinetics. PATIENTS AND METHODS: An open-label, crossover, one-sequence study was cond...
Autores principales: | Shin, Yesong, Choi, Chungam, Oh, Eun Sil, Kim, Choon Ok, Park, Kyungsoo, Park, Min Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789683/ https://www.ncbi.nlm.nih.gov/pubmed/36573067 http://dx.doi.org/10.2147/DDDT.S383157 |
Ejemplares similares
-
Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023) -
Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
por: Kim, Choon Ok, et al.
Publicado: (2016) -
Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018) -
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
por: Gu, Namyi, et al.
Publicado: (2014) -
Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
por: Kim, Heeyoung, et al.
Publicado: (2023)